MEDGENERA
  • Sections
    • NEWLY PUBLISHED
    • News from Asia-pacific
    • News from Europe
    • News from USA
    • MEDGENERA ORIGINAL
    • ASSESSMENT
    • MARKET INSIGHTS
    • DRUG TRIAL
    • PROGRESSIVE REVIEW
    • APPS & IMPLANTS
  • About us
  • Plans
  • Education
  • Get Online Training
  • Login
  • Webinar
0
  • Login
  • Get 1-Free month
  • Online Course
  • About us
  • BIORISE
  • Plans
  • BUSINESS
  • CAREER
  • HEALTHCARE & MEDICINE
  • IN-DEPTH STORIES
  • KNOWLEDGE CENTRE
  • MEDGENERA EXCLUSIVE
  • NEWLY PUBLISHED
  • News from Asia-pacific
  • News from Europe
  • News from USA
  • RESOURCE CENTRES
  • TECHNOLOGY

Category: MARKET INSIGHTS

Proportion
Tiash SahaDecember 30, 2019

Skin Cancers: The Sunny Challenge of Future (Potential Drugs and Treatments in Development)

KEY POINTS Ozone depletion, greenhouse gas-induced global warming, rising earth temperature is interacting to put a severe effect on human ...

Proportion
Pankaj MishraNovember 30, 2018

Billion Dollars Healthcare Startups (2018)

KEY POINTS A unicorn is a startup company with a current valuation of US$1 billion or more. Medgenera DATALABS has ...

Proportion
Tiash SahaAugust 24, 2018

Telemedicine a Blooming Area, Global Investments to Reach ~1 Billion in 2018: Medgenera Report

KEY POINTS About $725.9 million has been invested in telemedicine segment in 2017 by the global investors: Report Telemedicine is ...

Proportion
Tiash SahaApril 25, 2018

Pharma Giants Gradually Embracing Digital Healthcare Technologies

Big pharma players including Novartis, Roche, Pfizer, Sanofi are embracing digital technologies to deliver better to the patients. FDA’S 2018 Strategic Policy Roadmap indicates increasing number of digital health clearances in coming times with revised regulatory processes.

Proportion
Tiash SahaApril 10, 2018

Is Novartis Betting High to Give First FDA-Approved Gene Therapy for Spinal Muscular Atrophy?

Novartis bets high by acquiring the non-earning US-based gene therapy firm AveXis for $8.7 billion. But, AveXis' novel gene therapy- AVXS-101 could be a “game-changing” treatment for SMA patients and could turn out to be a potential blockbuster for Novartis, if approved.

Proportion
Tiash SahaMarch 15, 2018

‘Breath Biopsy’ Stands in Competition with ‘Liquid Biopsy’ as Next-Gen Cancer Diagnostics

KEY POINTS Breath Biopsy analyzes individual’s breath for biomarkers, signifying the metabolic conditions and cancer diagnosis of the person. GlaxoSmithKline ...

Proportion
Tiash SahaMarch 12, 2018

Sanofi’s Cholesterol-Lowering, Praluent® Wins Big Battle; will Become Cost-Effective

KEY POINTS Praluent is a cholesterol-lowering monoclonal antibody, significantly reduces the combined risk of cardiovascular problems and related deaths in ...

Proportion
Tiash SahaFebruary 15, 2018

9 Most Valuable Drugs Under Development (2018)

KEY POINTS The top 9 drugs currently under research and developments are ranked based on their Net Present Value. These ...

Proportion
Tiash SahaFebruary 8, 2018

Bristol-Myers Squibb Rises High with the Star Performer ‘Opdivo’

KEY POINTS Bristol-Myers Squibb’s (BMS) has shown stellar growth in its revenue (by 7 percent) in 2017. BMS’s Immuno-oncology drug, ...

Proportion
Tiash SahaFebruary 7, 2018

mRNA Therapy Startup Moderna Deck up its Value to $7 Billion

KEY POINTS With the latest equity financing of US $500M, Moderna is now the most valued healthcare unicorn startup in ...

  • 1
  • 2
Privacy Policy Terms Payment Policy Education Contact Us About us